Company Overview of Aragon Pharmaceuticals, Inc.

Snapshot

People

Overview Board Members Committees

Executive Profile

Charles L. Sawyers BA,M.D., Ph.D.

Co-Founder and Scientific Advisor, Aragon Pharmaceuticals, Inc.

Age	Total Calculated Compensation	This person is connected to 15 Board Members in 15 different organizations across 16 different industries. See Board Relationships
53	--

Background

Dr. Charles L. Sawyers, BA, M.D., Ph.D. is a Co-Founder of Aragon Pharmaceuticals Inc. and serves as its Scientific Advisor. Dr. Sawyers co-founded Agensys, Inc. and involved with consultancy of several oncology companies. His work focuses on how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. Dr. Sawyers played a key role in the clinical development of Gleevec® (imatinib). He spent nearly two decades at the University ... of California, Los Angeles (UCLA). Dr. Sawyers serves as the Chairman of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center in New York. He has been President of the Board at American Association For Cancer Research since April 2013. He serves as a Director of Novartis International AG. Dr. Sawyers has been a Director of Novartis AG since 2013. Dr. Sawyers serves as a Director of American Association For Cancer Research. He serves as a Member of Scientific Advisory Board of AVEO Pharmaceuticals, Inc., Nextech Invest Ltd. (formerly Nextech Venture Ltd.), Exelixis, Inc., Boston Millennia Partners, and Piramed Limited. He serves as a Member of Scientific Advisory Board at Housey Pharmaceutical Research Laboratories LLC and of TRACON Pharmaceuticals, Inc. He serves as a Member of Scientific Advisory Board and Member of Cancer Center Advisory Board of St. Jude Children's Research Hospital, Inc. Dr. Sawyers serves as a Member of Council of Scientific Advisors of The Translational Genomics Research Institute. He serves as a Member of Scientific Advisory Board at Blueprint Medicines Corp. He has been a Member of the Scientific Advisory Board of Agios Pharmaceuticals, Inc. since February 2009. He serves as a Director of Prostate Cancer Program and UCLA's Jonsson Comprehensive Cancer Center. He serves as Peter Bing Professor at the UCLA School of Medicine and is a Member of the Institute of Medicine and the National Academy of Sciences. Dr. Sawyers is a Howard Hughes Medical Investigator. He served as President of the American Society of Clinical Investigation, served on the National Cancer Institute's Board of Scientific Councillors. His research is best demonstrated through his studies of BCR-ABL tyrosine kinase function in chronic myeloid leukemia, his work at Brian Druker and Novartis in the development of the kinase inhibitor imatinib/Gleevec as primary therapy for CML, and his discovery that imatinib resistance is caused by BCR-ABL kinase domain mutations. He led preclinical and clinical studies of the novel Abl kinase inhibitor BMS-354825. Dr. Sawyers served as a Member of Scientific & Clinical Advisory Board at Medivation, Inc. He has received numerous honours and awards including Howard Hughes Medical Institute Physician Research Fellow from 1991 to 1993, Cheryl Whitlock Prize for Leukaemia Research in 1994, Franklin D Murphy Prize in 1998, Stohlman Scholar, Leukaemia and Lymphoma Research Society in 2000. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award. He completed a Residency in Internal Medicine at the University of California, San Francisco, Medical Center and a Clinical Fellowship in Hematology/Oncology and a Post-Doctoral Fellowship in Molecular Biology at the UCLA School of Medicine. Dr. Sawyers has a Ph.D. degree. Dr. Sawyers has undergraduate degree, a B.A. from Princeton University and an M.D. from The Johns Hopkins University.

Read Full Background